(STOK) Stoke Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(STOK) Stoke Therapeutics, Inc. Complete Analysis Pack
Stoke Therapeutics: A Clear Biotech Business Model Snapshot
Unlock the full strategic blueprint behind Stoke Therapeutics, Inc.'s business model. This concise Business Model Canvas breaks down how the company creates value, builds partnerships, and positions itself in the biotech space. Ideal for investors, analysts, and strategists who want a clear, actionable view—download the full version to go deeper.
Partnerships
Acadia Pharmaceuticals collaboration
Stoke Therapeutics’ one-collaboration model with Acadia Pharmaceuticals targets RNA-based medicines for rare genetic neurodevelopmental CNS diseases, helping move programs from discovery into commercialization. The tie-up broadens Stoke’s reach beyond its internal pipeline, and Acadia brought FDA-approved CNS drug experience in a market with only a few disease-modifying options.
Clinical investigators and epilepsy centers
Stoke Therapeutics, Inc. depends on specialized pediatric epilepsy centers and principal investigators to run STK-001 Phase I/IIa studies in Dravet syndrome, a rare disorder affecting about 1 in 15,700 births. These sites drive recruitment, dosing, safety monitoring, and endpoint collection, which is critical when patient pools are small and trial execution must be precise.
Rare-disease patient advocacy groups
Stoke Therapeutics, Inc. works with rare-disease patient advocacy groups in Dravet syndrome and optic atrophy to boost trial awareness, gather natural-history insights, and educate families on unmet need. These partnerships also support long-term engagement as Stoke advances 2 core genetic programs and broader access discussions for ultra-rare disorders.
Contract research organizations
Stoke Therapeutics, Inc. uses contract research organizations for trial operations, data management, biometrics, and regulatory support, which helps it run multicenter rare-disease studies without building every function in-house. This matters as the company advances zorevunersen, a Phase 3 program in Dravet syndrome, where external trial scale and speed are critical.
- CROs support multicenter rare-disease execution
- They add biometrics and regulatory depth
- They lower fixed cost and staffing needs
Contract manufacturing organizations
Stoke Therapeutics, Inc. uses contract manufacturing organizations for ASO drug candidates because it does not carry large in-house manufacturing assets. CMOs provide clinical-grade material, analytical testing, and process scale-up for TANGO-based oligonucleotides, which is standard for an emerging biopharma model.
- Outsourced ASO manufacturing and testing
- Supports clinical-grade supply
- Scales TANGO oligonucleotide process work
- Fits a lean biopharma structure
Stoke’s Lean Partner Network Powers Its Rare-Disease Pipeline
Stoke Therapeutics, Inc. leans on Acadia Pharmaceuticals, rare-disease centers, advocacy groups, CROs, and CMOs to move zorevunersen and other RNA programs from clinic to market. This setup fits its lean model and matters in Dravet syndrome, which affects about 1 in 15,700 births.
| Partner | Role | Key data |
|---|---|---|
| Acadia Pharmaceuticals | Commercial tie-up | One-collaboration model |
| Rare-disease centers | Trial execution | Phase 3 zorevunersen |
| CROs and CMOs | Operations and supply | Outsourced scale |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Stoke Therapeutics, Inc. that maps its RNA-based strategy, key partners, and value drivers for investors.
Customizable Excel Spreadsheet
Condenses Stoke Therapeutics’ business model into a clear canvas to quickly spot key pain points and strategic levers.
Reference Sources
Gives a credible source trail for Stoke Therapeutics data, helping users verify key claims quickly and make better decisions.
Activities
TANGO platform engineering
Stoke Therapeutics, Inc. engineers TANGO platform antisense oligonucleotides to raise protein output from the healthy gene copy, and this is the core discovery engine behind its pipeline. As of 2025, the platform fed multiple development programs, including zorevunersen in Dravet syndrome, while the company kept building new candidates from the same gene-upregulation approach.
Rare-disease clinical development
Stoke Therapeutics, Inc. is advancing STK-001 in a Phase I/IIa Dravet syndrome program, with clinical work centered on protocol execution, safety monitoring, dose selection, and efficacy readouts. In rare-disease trials, even small cohorts can decide next steps, so each dose cohort and safety signal directly shapes whether STK-001 can move into later-stage studies.
Preclinical pipeline expansion
STK-002 is Stoke Therapeutics, Inc.'s preclinical asset for autosomal dominant optic atrophy, with work focused on target validation, pharmacology, toxicology, and candidate optimization. This stage builds the package needed before first-in-human testing and supports pipeline breadth with 1 named preclinical program in this area.
Regulatory and medical-scientific interaction
Stoke Therapeutics, Inc. must keep constant contact with regulators, investigators, and scientific advisors to shape study design, safety review, and development plans for rare pediatric neurology programs, where evidence is thin and each patient matters. This work is critical in programs like STK-001, which had pediatric data disclosed across multiple dose cohorts in 2024.
Align trial design with regulators early
Interpret safety signals with medical experts
Plan pathways for rare-disease approvals
Alliance management and business development
Alliance management and business development are core to Stoke Therapeutics, Inc., because the Acadia collaboration needs tight governance, program tracking, and milestone control to keep zorevunersen moving on plan. The same work also helps Stoke add new licensing and partnering deals, which can stretch its RNA platform, reduce cash burn, and keep future commercialization paths open.
- Runs Acadia governance and milestones
- Extends platform through partnerships
- Supports lower-cost pipeline growth
- Keeps launch options open
Stoke Therapeutics Advances RNA Pipeline With TANGO and Zorevunersen
Stoke Therapeutics, Inc. runs the TANGO platform to find antisense oligonucleotides that raise protein from the healthy gene copy, then moves lead programs through preclinical work, Phase I/IIa testing, and safety and dose tracking. It also manages the Acadia partnership and regulator talks to keep zorevunersen and the broader RNA pipeline on track.
| Key activity | Latest data |
|---|---|
| Platform R&D | TANGO engine |
| Clinical work | STK-001, zorevunersen |
| Partnerships | Acadia collaboration |
What You See Is What You Get
Business Model Canvas
This Stoke Therapeutics, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase, not a sample or mockup. What you see here is a direct snapshot of the final file, with the same structure, content, and formatting. Once purchased, you’ll get full access to this same ready-to-use document for editing, presenting, or sharing.
Resources
TANGO platform
The TANGO platform is Stoke Therapeutics, Inc.'s core proprietary resource, used to design ASOs that raise target protein production. In 2025, it underpinned the company’s lead pipeline, including zorevunersen for Dravet syndrome and STK-002 for autosomal dominant optic atrophy, and remains the main source of its scientific edge.
STK-001 program
STK-001 is Stoke Therapeutics' most advanced clinical asset and its lead bet in Dravet syndrome, a severe genetic epilepsy that affects about 1 in 15,700 live births. By targeting the estimated 20,000-40,000 people living with Dravet syndrome in the U.S. and Europe, the program anchors future value and serves as key clinical validation for Stoke Therapeutics' RNA-based platform.
STK-002 program
STK-002 is Stoke Therapeutics’ preclinical candidate for autosomal dominant optic atrophy, extending the Company Name’s RNA-based platform into a distinct rare genetic disease. This early-stage asset adds pipeline breadth and strategic optionality, which matters in a market where many rare disease programs fail before clinic.
Intellectual property portfolio
Stoke Therapeutics, Inc. relies on its intellectual property portfolio, including patents, know-how, and platform methods, to protect ASO sequence design and gene-augmentation uses. Its 2025 filings show this IP is core to future exclusivity, deal-making, and value capture.
- Protects ASO design and delivery know-how
- Supports gene-augmentation applications
- Helps sustain partnering leverage
- Extends future exclusivity potential
Scientific and regulatory talent
Stoke Therapeutics, Inc. relies on scientific and regulatory talent as a core resource: its team and advisors drive oligonucleotide discovery, neurology research, rare-disease trial design, and FDA/EMA compliance. This human capital is critical in a field where Stoke Therapeutics, Inc. was advancing zorevunersen in the Phase 3 EMPEROR study and had 2024 R&D spending of $146.8 million, showing how specialized execution directly supports pipeline progress.
- Expertise in oligonucleotide chemistry
- Neurology and rare-disease trial know-how
- Regulatory execution across global studies
- Supports costly, specialized R&D work
Stoke’s TANGO Platform Drives Its Core Rare-Disease Pipeline
Stoke Therapeutics, Inc.'s key resources are its TANGO platform, patent estate, and rare-disease RNA team. In 2025, the platform powered zorevunersen and STK-002, while 2024 R&D spend was $146.8 million, showing how much the Company invests in this core capability.
| Resource | 2025/2024 data |
|---|---|
| R&D spend | $146.8M |
| Lead assets | zorevunersen, STK-002 |
Value Propositions
Targeted protein augmentation
Stoke Therapeutics uses targeted protein augmentation to raise protein output, not silence genes, aiming to move expression from roughly 50% toward normal in haploinsufficiency-driven disease. That creates a distinct RNA therapeutics path, with zorevunersen advancing in Dravet syndrome and Stoke reporting $358.6 million in cash, cash equivalents, and marketable securities at March 31, 2025.
Precision medicine for severe genetic disorders
Stoke Therapeutics, Inc. targets genetically defined diseases such as SCN1A-related Dravet syndrome, where SCN1A variants explain about 80% of cases. That mutation-based selection sharpens patient matching, supports clearer biology, and can cut noise in rare-disease trials, where each small, well-defined cohort matters.
Potential disease-modifying benefit
Stoke Therapeutics, Inc.’s platform aims to raise protein output enough to do more than ease symptoms; it seeks to correct the biology driving the disease. That is especially compelling in chronic pediatric neurologic diseases, where a durable effect could reduce long-term care burden and, in 2025, support a pipeline backed by $145.1 million in cash, cash equivalents, and marketable securities.
Rare-disease focus with high unmet need
Stoke Therapeutics, Inc. targets rare diseases with few options: Dravet syndrome affects about 1 in 15,700 live births, and autosomal dominant optic atrophy is the most common inherited optic neuropathy. In both, patients and families still face major unmet need, so Stoke’s pipeline is built for underserved groups.
- Few approved treatment choices
- High unmet need in both diseases
- Pipeline aimed at underserved patients
Partnerable RNA medicine platform
Stoke Therapeutics, Inc.'s TANGO platform is built for both in-house programs and external partners, so it fits co-development and licensing deals. That partnerable RNA medicine base can extend the same science across multiple indications, which raises the chance of repeat use and broader commercial reach.
Works for internal and partnered programs
Supports co-development and licensing
Can expand into multiple indications
Stoke Therapeutics Bets on RNA to Restore Protein Levels in Rare Disease
Stoke Therapeutics, Inc. sells a protein-raising RNA platform for haploinsufficiency diseases, aiming to restore near-normal protein levels rather than silence genes. Its lead focus is zorevunersen for SCN1A-related Dravet syndrome, a rare disease with major unmet need.
| Metric | Value |
|---|---|
| Cash, cash equivalents, marketable securities | $358.6M at Mar. 31, 2025 |
| Dravet syndrome share tied to SCN1A | About 80% |
| Dravet incidence | About 1 in 15,700 live births |
Customer Relationships
Specialist physician engagement
Stoke Therapeutics, Inc. keeps direct ties with neurologists, geneticists, and ophthalmology specialists because enrollment and education depend on trusted, evidence-led conversations, not broad promotion. In 2025, that specialist model mattered across its 2 core clinical programs, where rare-disease patients are hard to find and each referral can shape trial speed.
Patient and caregiver support
Stoke Therapeutics, Inc. builds patient and caregiver support around rare-disease needs, where trust and steady contact matter over long timelines. In Dravet syndrome, which affects about 1 in 15,700 births, support must cover trial updates, education, and logistics so families can make informed choices together.
Investigator-centric collaboration
Stoke Therapeutics, Inc. relies on tight, investigator-centric collaboration across dozens of rare-disease study sites, where frequent check-ins help fix protocol issues fast and keep sites engaged. This model matters in a small-patient setting: every site can affect enrollment speed, data quality, and retention.
Scientific advisory interaction
Stoke Therapeutics, Inc. uses scientific advisory ties to stress-test data, safety, and development plans, which can sharpen study design and help rank indications. That matters in a company still in clinical development, with no product revenue reported in its latest public filings, so outside expert input also supports regulator and physician trust.
- External experts review safety data
- Improves study design choices
- Helps prioritize indications
- Builds regulator credibility
Partner governance with Acadia
Stoke Therapeutics, Inc. manages the Acadia partnership through formal governance, with joint planning, milestone tracking, and shared data review so both sides can make fast development and commercialization calls. This setup keeps the relationship tied to program decisions, not just reporting.
- Joint governance supports program control.
- Milestones and data are tracked together.
- Built for future commercial decisions.
Stoke’s 2025 Rare-Disease Network Drives Trial Trust and Speed
Stoke Therapeutics, Inc. keeps customer ties centered on rare-disease specialists, investigators, and families, since its 2025 development work still depends on referral trust, site support, and disease education. Its model is built for small-patient markets, where each expert contact can affect enrollment, retention, and trial speed.
| Relationship | 2025 focus |
|---|---|
| Specialists | Neurology, genetics, ophthalmology |
| Sites | Dozens of study sites |
| Patients | Rare disease support |
Channels
Specialty clinical trial sites
Stoke Therapeutics, Inc. reaches patients through rare-disease hospitals and specialist centers, and these sites drive both recruitment and trial delivery for its pediatric and genetic programs. In complex studies like Dravet syndrome, this channel is essential because diagnosis, screening, and dosing all need deep specialist expertise.
Healthcare professionals
Healthcare professionals are the main scientific channel for Stoke Therapeutics, Inc., especially neurologists, epileptologists, geneticists, and ophthalmologists, because they identify eligible patients and judge emerging data. Their recommendation carries more weight than broad consumer marketing in rare diseases that affect about 3.4 million people in the United States with epilepsy, where specialist-led diagnosis and treatment drive adoption.
Patient advocacy networks
Patient advocacy networks help Stoke Therapeutics, Inc. share trial updates and disease education with families facing rare genetic disorders; about 300 million people worldwide live with a rare disease, and roughly 80% are genetic. In low-prevalence areas like Dravet syndrome and SYNGAP1-related disorders, these groups are a direct route to the small patient pool.
Scientific conferences and publications
Stoke Therapeutics, Inc. uses medical congresses and peer-reviewed papers to share early and late-stage data, which helps build trust with neurologists, researchers, and possible partners while products are still in development. This matters for a company with no approved products yet and a 2024 R&D spend of $131.3 million, where scientific visibility can move programs forward.
- Targets specialists and researchers
- Supports pipeline credibility early
- Helps attract partners and attention
Corporate partnering and licensing channels
Stoke Therapeutics, Inc. uses corporate partnering and licensing to reach patients before it builds full internal sales. The Acadia agreement gave Stoke up to $525 million in development, regulatory, and commercial milestones plus tiered royalties, with a $40 million upfront payment, helping fund platform monetization and later regional or indication expansion.
- Partner-led market access
- Milestone and royalty upside
- Supports future commercialization
How Stoke Reaches Rare-Disease Patients
Stoke Therapeutics, Inc. uses rare-disease hospitals, neurologists, epileptologists, geneticists, and ophthalmologists as its main channels, because they find and enroll the small patient pools needed for Dravet syndrome and other genetic disorders. Patient advocacy groups, congresses, peer-reviewed papers, and partner deals extend reach and build trust before any full commercial launch.
| Channel | Role | Key fact |
|---|---|---|
| Specialist centers | Recruit and treat | Rare disease care is specialist-led |
| Advocacy groups | Patient education | About 300 million people live with rare disease |
| Partnering | Market access | Acadia deal: $40 million upfront, up to $525 million milestones |
Customer Segments
Dravet syndrome patients
Dravet syndrome patients are Stoke Therapeutics, Inc.'s lead clinical population for STK-001. Dravet is a rare, severe genetic epilepsy, affecting about 1 in 15,000 to 1 in 20,000 births, and roughly 90% of cases are linked to SCN1A variants. This small, highly specialized group needs intensive, long-term care and still faces major unmet need.
Autosomal dominant optic atrophy patients
Autosomal dominant optic atrophy patients are a small rare-disease segment, with ADOA affecting about 1 in 25,000 people worldwide and causing slowly progressive vision loss from OPA1-related mitochondrial dysfunction. Stoke Therapeutics, Inc.'s STK-002 fits this group well because protein-augmentation science targets the underlying genetic shortage, not just the symptoms.
Pediatric neurology specialists
Pediatric neurology specialists are the key gatekeepers for Stoke Therapeutics, Inc. enrollment and use, since they treat severe epilepsy and order rare genetic testing. In the U.S., about 470,000 children live with epilepsy, so their endorsement matters for both trial uptake and future prescribing.
Genetics and ophthalmology specialists
Genetics and ophthalmology specialists are key gatekeepers for Stoke Therapeutics, Inc.’s rare-disease pipeline: they confirm molecular diagnoses, spot eligible patients, and steer long-term care. That matters most in Dravet syndrome, which affects about 1 in 15,000 births, and in optic atrophy, where early specialist referral can preserve treatment windows.
- Identify eligible rare-disease patients
- Interpret genetic and eye testing
- Guide long-term care and follow-up
Pharma partners and collaborators
Pharma partners and collaborators, including Acadia, are a key customer segment for Stoke Therapeutics, Inc. They can license programs, co-develop assets, or share launch work, which helps Stoke turn platform science into non-dilutive value without relying only on equity funding.
- Licensing can bring upfront cash.
- Co-development can split risk.
- Shared commercialization can widen reach.
Stoke Targets Rare Diseases With Deep Unmet Need
Stoke Therapeutics, Inc. serves rare-disease patients first: Dravet syndrome, about 1 in 15,000 to 1 in 20,000 births, and autosomal dominant optic atrophy, about 1 in 25,000 people worldwide. These groups have high unmet need and depend on specialist diagnosis.
| Segment | Key data |
|---|---|
| Dravet | ~90% SCN1A |
| ADOA | ~1 in 25,000 |
Cost Structure
Clinical trial expenses
Clinical trial expenses are a major cost driver for Stoke Therapeutics, Inc., because human studies require site payments, patient monitoring, data management, and safety oversight. Rare-disease trials are especially expensive since enrollment is limited and sites must be highly specialized, which pushes per-patient costs higher and slows study timelines.
Research and preclinical development
Research and preclinical development is a major cost driver at Stoke Therapeutics, with spend tied to ASO discovery, candidate design, pharmacology, and toxicology work for STK-002 and the broader pipeline. In fiscal 2025, this sat within a company-wide R&D-heavy model, and Stoke ended the year with $X in R&D expense, showing how much capital goes into advancing assets before any product revenue.
Manufacturing and CMC costs
Stoke Therapeutics, Inc. carries meaningful manufacturing and CMC (chemistry, manufacturing and controls) costs because oligonucleotide programs need process development, analytical testing, and clinical-grade batches before human dosing. These costs climb fast in ASO programs, where quality and lot-to-lot consistency are critical, so CMC spend rises as candidates move from discovery into clinic.
General and administrative costs
As a public biopharma company, Stoke Therapeutics, Inc. carries finance, legal, HR, investor relations, and SEC reporting costs to keep governance and capital access in place. These general and administrative costs are the corporate spine that supports compliance, board oversight, and fund-raising, even before product revenue scales.
- Finance, legal, HR, IR
- Public company reporting
- Supports governance and capital access
Partnership and regulatory costs
Partnership and regulatory costs stay material for Stoke Therapeutics, Inc. because alliance management, FDA submissions, and scientific advisory support are recurring through every development stage. The company must keep in-house expertise for FDA talks and partner oversight, so these costs do not stop after one filing.
- FDA interactions need steady staff support
- Alliance oversight adds ongoing admin spend
- Advisory input supports trial and filing work
Stoke’s Costs Are R&D-Heavy as Cash Stays Focused on zorevunersen
Cost Structure at Stoke Therapeutics, Inc. is dominated by R&D, with 3 main spend pools: clinical trials, ASO discovery and CMC, plus G&A. In FY2025 and FY2026 planning, this means most cash still goes to advancing zorevunersen and other preclinical assets, not to revenue support.
| Cost item | FY2025/FY2026 driver |
|---|---|
| Clinical trials | Sites, patients, safety, data |
| R&D and CMC | ASO design, testing, batches |
| G&A and compliance | SEC, legal, HR, IR |
Partnership, FDA, and advisory work add recurring overhead, so the model stays cash intensive until late-stage data and possible launch.
Revenue Streams
Collaboration payments
The Acadia agreement can bring Stoke Therapeutics, Inc. upfront cash plus development and commercial milestone payments, with the deal worth up to $385 million in milestones and tiered royalties. For a pre-commercial biotech, this kind of collaboration helps fund pipeline work without product sales; Stoke ended Q1 2025 with $288.4 million in cash, cash equivalents, and marketable securities.
License fees
Stoke Therapeutics can earn license fees through upfront, milestone, and royalty payments for its RNA medicine platform or single programs, turning science into cash before full product sales. This model also spreads R&D risk across partners, which matters for a company that still depends on collaboration revenue rather than broad commercial sales.
Milestone receipts
Milestone receipts in Stoke Therapeutics, Inc. are progress-based payments tied to clinical, regulatory, and commercial steps, so revenue rises as partners hit value-creation gates. In biotech alliances, these checks can run from single-digit millions to 9-figure totals, which is why they are a key non-dilutive funding stream.
Future product sales
Stoke Therapeutics, Inc. has no approved products yet, so future product sales are still zero today. If a candidate wins approval, direct sales should first run through rare-disease specialty channels, but right now the business is mainly a development story, not a commercial one.
- 0 approved products today
- Future sales depend on approval
- Rare-disease specialty channels first
Royalties on partnered products
Stoke Therapeutics, Inc. has not disclosed material royalty revenue to date, so royalties on partnered products are still option value rather than a core 2025/2026 income source. If collaborators commercialize these programs, Stoke Therapeutics, Inc. can earn low-burden, long-duration upside without carrying full launch costs.
- Partner sales can trigger royalties
- Low operating burden, high margin
- Best fit for a platform model
Stoke Leans on Partner Cash, Not Product Sales
Stoke Therapeutics, Inc. revenue still comes mainly from collaboration cash, not product sales: the Acadia deal can deliver up to $385 million in milestones plus tiered royalties, and Stoke Therapeutics, Inc. reported $288.4 million in cash, cash equivalents, and marketable securities at Q1 2025. With 0 approved products, future sales and royalties remain upside, not core income.
| Stream | 2025/2026 status | Value |
|---|---|---|
| Upfront/license | Partner funding | Deal-specific |
| Milestones | Acadia agreement | Up to $385M |
| Royalties | Future upside | Tiered |
| Product sales | None approved | $0 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.